Livforsakringsbolaget Skandia, Omsesidigt
Position in EXEL — Exelixis, Inc.
CIK 1547926
Stockholm, V7
Position in EXEL
as of Jun 30, 2026
· filed Aug 18, 2026
Position Value
$15,980,379
+$5,639,472 QoQ
Shares Held
293,703
+21.8% QoQ
Ownership
0.119%
of shares outstanding
% of Portfolio
0.55%
of 13F equity value
Holder Rank
#104
of 754 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Livforsakringsbolaget Skandia, Omsesidigt holds $40,172,931 across 9 Biotechnology names. EXEL ranks #1 (39.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
293,703 | $15,980,379 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
114,905 | $9,990,989 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
124,100 | $9,713,307 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,780 | $2,871,099 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
772 | $481,372 | |
| 6 | INSM |
INSMED Inc
|
4,412 | $470,407 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,000 | $301,030 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
1,000 | $187,280 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,980,379 | 293,703 | Shares | Sole | 2026-08-18 | |
| 2026-03-31 | $10,340,907 | 241,103 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $12,769,870 | 291,350 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $4,239,445 | 102,650 | Shares | Sole | 2025-11-18 | |
| 2025-06-30 | $3,442,648 | 78,100 | Shares | Sole | 2025-07-11 | |
| No filing history on record for this holder in this stock. | ||||||